Klinische Forschung Osnabrueck — Clinical Trial Site

25 Registered trials

8 Currently recruiting

Organisation

Klinische Forschung Osnabrueck

Location

Osnabrueck, Germany

Identifier

ORG-100043552

Address

Hakenstraße 1, Innenstadt, 49074, Germany

Departments

2165
2208:NA
Dermatology
DEU03298: Klinische Forschung Osnabrück
KliFOs - Klinische Forschung Osnabrück
KLIFOS - Klinische Forschung Osnabrueck
KLIFOs Klinische Forschung
Klinische Forschung
Klinische Forschung Osnabrück
Klinische Forschung Osnabrueck
N/A
NA

Clinical trials at this site (25)

Search interface

Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending

2023-507427-28-00 seasonal allergic rhinitis and/or rhinoconjunctivitis 5
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 10 2024-11-20
A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting

2025-524580-21-00 Grass pollen induced allergic rhinitis or rhinoconjunct 10 2026-06-01
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
Dose-finding study of LAD603 in adults with alopecia areata Recruiting

2025-523342-27-00 Alopecia areata 4 2026-04-10
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting

2024-519081-49-00 Moderate to severe atopic dermatitis 4 2025-10-28
A 16-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g Compared to a Dummy Cream in Adult Subjects With Mild t… Recruiting

2024-518856-21-00 Mild to severe palmoplantar pustulosis 4 2025-08-28
Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting

2023-508520-36-00 Seasonal allergic rhinitis/rhinoconjunctivitis induced 5 2024-09-06
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended

2022-502188-39-00 Dermatitis atopic 4 2023-09-27
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended

2024-511225-64-00 Alopecia areata 4 2024-09-18
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended

2023-504942-75-01 Moderate to Severe Allergic Rhinitis/Rhinoconjunctiviti 5 2024-08-22
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Chronic Spontaneous Urticaria 4 2023-11-23
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
Moisturiser effect on atopic dermatitis relapse prevention in children Ended

2022-501184-41-00 atopic dermatitis/eczema 6 2023-02-13
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment wit… Ended

2024-514548-10-01 Mild to moderate atopic dermatitis 3 2021-07-26